{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-24-015856","form_type":"8-K","ticker":"RARE","cik":"0001515673","company_name":"Ultragenyx Pharmaceutical Inc.","filed_at":"2024-02-15T23:59:59+00:00","discovered_at":"2026-05-14T18:03:24.454734+00:00","generated_at":"2026-06-06T01:10:42.373634+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Ultragenyx FY2023 revenue $434M (+20% YoY); net loss narrows; 2024 guide $500-530M","bullets":["Total revenue 2023 $434M (+20% YoY); Crysvita $328M (+17%), Dojolvi $71M (+27%).","Net loss 2023 $607M ($8.25/sh) vs $707M ($10.12) in 2022; Q4 loss $123M ($1.52).","Cash $777M at Dec 31, 2023; 2024 net cash used in ops expected <$400M.","2024 guidance: total revenue $500-530M, Crysvita $375-400M, Dojolvi $75-80M.","Pipeline: DTX401 GSDIa Ph3 data H1 2024; GTX-102 Angelman expansion data H1 2024; setrusumab OI Ph3 enrollment Q1 end."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-24-015856","json":"https://secwatch.observer/filing/0000950170-24-015856.json","markdown":"https://secwatch.observer/filing/0000950170-24-015856.md","text":"https://secwatch.observer/filing/0000950170-24-015856.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1515673/000095017024015856/0000950170-24-015856-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1515673/000095017024015856/rare-20240215.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-06T01:10:42.373634+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"1016bd2f28cab6c59bf585c7e35e6aeb677cc89a","claim":"Ultragenyx Pharmaceutical Inc. updated its the quarter and full year ended December 31, 2023 guidance (reaffirmed).","evidence_excerpt":"On February 15, 2024, Ultragenyx Pharmaceutical Inc. issued a press release announcing its financial results for the three months ended December 31, 2023 and the year ended December 31, 2023","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1515673/000095017024015856/0000950170-24-015856-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the quarter and full year ended December 31, 2023"},{"label":"Guidance","value":"reaffirmed"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}